Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Tumor-Agnostic 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 689Cyclophosphamide 614Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 228Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 175Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106Tacrolimus 105obinutuzumab 104Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Valacyclovir × Lymphoid × Clear all
NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
46 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT00562770 2012-07-31

Oral Valganciclovir Versus Valacyclovir

M.D. Anderson Cancer Center

Phase 2 Completed
46 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡